WallStSmart

Becton Dickinson and Company (BDX)vsMiniMed Group, Inc. Common Stock (MMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 617% more annual revenue ($22.23B vs $3.10B). BDX leads profitability with a 5.1% profit margin vs -10.7%. BDX earns a higher WallStSmart Score of 65/100 (B-).

BDX

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

MMED

Avoid

35

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 5.0Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+9.9%)

Margin of Safety

+9.9%

Fair Value

$200.45

Current Price

$151.16

$49.29 discount

UndervaluedFair: $200.45Overvalued

Intrinsic value data unavailable for MMED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

MMED3 strengths · Avg: 9.3/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
25.4x4/10

Moderate valuation

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

MMED4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Profit MarginProfitability
-10.7%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : MMED

The strongest argument for MMED centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Piotroski F-Score.

Key Dynamics to Monitor

BDX profiles as a value stock while MMED is a growth play — different risk/reward profiles.

MMED is growing revenue faster at 15.6% — sustainability is the question.

BDX generates stronger free cash flow (546M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (65/100 vs 35/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

MiniMed Group, Inc. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Want to dig deeper into these stocks?